As shown by in vivo data, except Trastuzumab and CAN017 alone, other single drugs or combination treatments displayed a certain degree of tumor inhibition, among which Trastuzumab combined with HER3-targeted antibody or MEK inhibitor demonstrated both high efficacy and good tolerance, suggesting a quite promising strategy for future clinical trials. Here, MAP2K7 is linked to neoplasm.